Carotid StenosisPhase 4NCT04662177
Co-administration of Dexmedetomidine in Carotid Endarterectomy (CEA)
A Phase 4 study testing Dexmedetomidine in people with Carotid Stenosis, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
Trial summary
All neurosurgical patients at the Neurosurgery University Hospital Bern who will be operated for carotid endarterectomy (CEA) are routinely operated in deep anae¬sthesia with suppression of the electrical activity of the electroencephalogram (EEG). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carotid Stenosis
- What is being tested?
- Dexmedetomidine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 23 participants
- Where
- 1 siteSwitzerland
- Study dates
- 21 Nov 2018to 4 Dec 2020
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- ASA physical status 1-4
- written informed consent provided.
Who cannot join
- Age <18 years
- higher grade atrioventricular block without pacemaker
- severe hypovolaemia or bradycardia
- uncontrolled hyper- or hypotension
- hypersensibility concerning the active substance dexmedetomidine or any other component
- serve liver disease
Show all 11Show fewer
- known malignant hyperthermia
- cardiovascular instability or severe heart failure (> NYHA III)
- limited peripheral autonomic activity
- pregnancy
- rejection or lack of consent of the patient or their relatives.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Co-administration of Dexmedetomidine in Carotid Endarterectomy (CEA) With Intraoperative SSEP and MEP Monitoring: A Single-centre Prospective Randomized Controlled Trial
All neurosurgical patients at the Neurosurgery University Hospital Bern who will be operated for carotid endarterectomy (CEA) are routinely operated in deep anae¬sthesia with suppression of the electrical activity of the electroencephalogram (EEG). To achieve this suppression of the EEG activity (burst suppression, BS) high effector concentrations (Cet) of Propofol doses are needed. However, a protracted infusion of large amounts of Propofol to reach a BS during the operation can lead to accumulation and a protracted wake-up phase with poorer neurological assessability. Somatosensory evoked potentials (SSEP), and trans-cranial Doppler flow velocity in the middle cerebral artery are measured to detect ischemia until the operation. The SSEPs are used to verify the functional integrity of the nervous system in combination of the EEG and both together exclude severe global ischemia during the operation.
The central acting α2-agonist Dexmedetomidine could help to reduce the amount of Propofol without influencing electrophysical studies. However, no data are currently known for practical use in carotid endarterectomy with Propofol with co-administration of Dexmedetomidine in conjunction with electrophysiological studies (SSEPs and MEPs).
Read the detailed description
In the investigators clinic, as a neuroprotective measure, all neurosurgical patients operated for carotid endarterectomy (CEA) are routinely operated in deep anaesthesia with suppression of the electrical activity of the electroence-phalogram (EEG). To achieve this suppression of the EEG activity (burst suppression, BS) high effector concentrations (Cet) of Propofol doses are needed. However, a protracted infusion of large amounts of Propofol to reach a BS during the operation can lead to accumulation and a protracted wake-up phase with poorer neurological assessability.
Somatosensory evoked potentials (SSEP), and trans-cranial Doppler (TCD) flow velocity in the middle cerebral artery are measured to detect ischemia. A significant decrease in TCD velocity and/or SSEPs amplitudes during cross-clamping of the internal carotid artery (ICA) gets treated with an adapted increase of arterial blood pressure or placement of a shunt. Intraoperative monitoring and recording of data in every patient undergoing CEA median nerve SEPs and MCA flow velocity have been constantly monitored by an additional intraoperative monitoring (IOM) technician who has been trained and certified in the assessment of intraoperative monitoring. The median nerve SEP amplitudes are recorded at least at these events: baseline value before skin incision, EEG burst suppression before cross clamping of the internal carotid artery, at time of ICA cross clamping, 10 minutes after cross clamping or immediately after placement of shunt (ICA clamping), reperfusion of ICA and haemostasis / end of surgery. The predefined criterion for temporary shunting was the reduction of more than 50% of the SEP amplitude.
Median nerve somatosensory evoked potentials (SEPs) were performed by stimulation at the wrist with a pair of needle electrodes (Inomed Germany®). This is a single pulse stimulation with 0.5 ms pulse duration and a low repetition rate ranging from 0.7 - 2.3 Hz. Recording is performed via corkscrew electrodes placed accordingly to the 10-20-EEG system on the patient scalp. For the right median nerve SEP C3´/Fz and for the left median nerve SEP C4´/Fz is chosen as standard derivation. Alternatively, Cz' or the contralateral Cp' served as reference to improve quality of recording. To improve the signal to noise ratio the responses are averaged 150-200 times.
The investigator use the somatosensive evoked potentials (SSEPs) to verify the functional integrity of the nervous system. Standardized surgical and anaesthesiological measures at the CEA with defined EEG endpoints and depending on the anaesthetic effect can - in normal EEG and SSEPs - effectively exclude severe global ischemia. The effects of burst suppression and the volatile anaesthetics on SSEPs were also investigated and showed no significant difference. Since 2016, motor-induced evoked potentials (MEPs) have also been used, which are, however, suppressed by volatile anaesthetics in a dose-dependent manner. On the other hand, Dexmedetomidine in combination with Propofol seems to suppress only insignificantly.
The indication spectrum for the centrally acting α2-agonist Dexmedetomidine has been increasingly extended since its approval in Switzerland. In addition to the use of Dexmedetomidine in the intensive care units, Dexmedetomidine is also increasingly being used perioperatively up to premedication in children. In some studies, an anaesthetic reduction of 40-60% could be achieved or the opioid consumption after the addition of a α2-agonist could be reduced by 50-75%. The blood pressure response to a Dexmedetomidine dose depends on the rate of infusion). In addition, administration of Dexmedetomidine does not result in respiratory depression or compromising of the respiratory tract. It has been shown that Dexmedetomidine can cause a "sleep-like" sedation state and this state can be interrupted by verbal stimuli), examined the EEG activity in sedations on voluntary subjects compared to a control group with physiological sleep pattern. In this study, it was shown that the EEG spindle activity in subjects with Dexmedetomidine infusion was comparable to that of a physiological non-rapid eye-movement (nonREM) sleep stage II in the control tests. The authors concluded from their investigations that a "sleep-like state" (stage II non-REM) can be achieved by the Dexmed-etomidine infusion. However, no data are currently known for practical use in carotid endarterectomy with Propofol and Dexmedetomidine in conjunction with electrophysiological studies (somatosensory evoked potentials (SSEP) and motor evoked potentials (MEP)).
In addition, there is a high risk of postoperative delirium (POD) in many of these patients. This was examined in a recently published Lancet study by Xian Su and colleagues in 700 patients with non-cardiac interventions in elderly patients). A reduction of the delirium incidence from 23% to 9% was found after a low-dose Dexmedetomidine dose of 0.1 μg/kg body weight/h. In addition, Dexmedetomidine is attributed a neuroprotective effect against ischemic and hypoxic influences). Other animals-experimental studies indicate neuroprotection in ischemic insult and subsequent reperfusion).
- Conditions
- Carotid Stenosis
- Being tested
- Dexmedetomidine
- Medical subject headings
- Carotid Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DexmedetomidineDrug
Also called Dexdor(R), Dexmedetomidine
The study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management.
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies | Experimental | The group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by continuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Receives: Drug: Dexmedetomidine |
| Group 2: Standard anaesthesia with propofol and electrophysiological studies | No intervention | The group 2 receive standard anaesthesia management. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect size concentration of propofol.
The primary study outcome is to determine whether the intervention reduces the effect size concentration of propofol.
Measured: until the operation
Secondary outcomes (1)
intraoperative propofol requirement
the intraoperative propofol requirement or consumption, duration from end of surgery to extubation, intraoperative electrophysiological parameters , intraoperative haemodynamic parameters, vasoactive substances, and fluid management. We will also measure the vigilance, Richmond Agitation Sedation criteria for the development of delirium and muscle force of the extremities in the intensive care unit in the first 24 hours after the end of the operation at. Furthermore, we will examine the perioperative urinary output in these patients during the Operation. Additionally, we want to examine the patients' use of painkillers and the need for rescue analgesics as well as the postoperative nausea and vomiting direct after the patient has been extubated and once during the stay in the intensive care unit.
Measured: until the operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2020
- Study start21 Nov 2018
- Primary completion16 Oct 2020
- Study completion4 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Carotid StenosisStudies of the same condition, open and under way.
- More trials run by Insel Gruppe AG, University Hospital BernThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomised controlled prospective trial in two groups. Group 1 will receive anaesthesia with propofol and co-administration of dexmedetomidine in conjunction with electrophysiological studies measuring somatosensory evoked potentials (SSEPs) and motor evoked potentials (MEPs). Group 2 will receive standard anaesthesia with propofol alone, in conjunction with electro¬physio¬logical studies measuring SSEPs and MEPs.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 23 participants (actual)
Sponsor and investigators
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Christian cv Vetter, MD, Principal investigator, University of Bern
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04662177
- Sponsor's protocol ID
- 2018-00220
- Other IDs
- 2018
- Status last verified
- Dec 2020
- First submitted
- 3 Dec 2020
- Last updated
- 19 Dec 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Vetter C, Meyer ER, Seidel K, Bervini D, Huber M, Krejci V. Co-administration of dexmedetomidine with total intravenous anaesthesia in carotid endarterectomy reduces requirements for propofol and improves haemodynamic stability: A single-centre, prospective, randomised controlled trial. Eur J Anaesthesiol. 2025 Mar 1;42(3):255-264. doi: 10.1097/EJA.0000000000002099. Epub 2024 Nov 11.
PubMed 39529482
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Co-administration of Dexmedetomidine in Carotid Endarterectomy (CEA) With Intraoperative SSEP and MEP Monitoring: A Single-centre Prospective Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04662177
- Acronym / sponsor ID
- 2018-00220
- Conditions
- Carotid Stenosis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 23 participants (actual)
- Lead sponsor
- Insel Gruppe AG, University Hospital BernUniversity, hospital or other
- Study start
- 21 Nov 2018 (actual)
- Primary completion
- 16 Oct 2020 (actual)
- Study completion
- 4 Dec 2020 (actual)
- First posted
- 10 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
All neurosurgical patients at the Neurosurgery University Hospital Bern who will be operated for carotid endarterectomy (CEA) are routinely operated in deep anae¬sthesia with suppression of the electrical activity of the electroencephalogram (EEG). To achieve this suppression of the EEG activity (burst suppression, BS) high effector concentrations (Cet) of Propofol doses are needed. However, a protracted infusion of large amounts of Propofol to reach a BS during the operation can lead to accumulation and a protracted wake-up phase with poorer neurological assessability. Somatosensory evoked potentials (SSEP), and trans-cranial Doppler flow velocity in the middle cerebral artery are measured to detect ischemia until the operation. The SSEPs are used to verify the functional integrity of the nervous system in combination of the EEG and both together exclude severe global ischemia during the operation.
The central acting α2-agonist Dexmedetomidine could help to reduce the amount of Propofol without influencing electrophysical studies. However, no data are currently known for practical use in carotid endarterectomy with Propofol with co-administration of Dexmedetomidine in conjunction with electrophysiological studies (SSEPs and MEPs).
Detailed description
In the investigators clinic, as a neuroprotective measure, all neurosurgical patients operated for carotid endarterectomy (CEA) are routinely operated in deep anaesthesia with suppression of the electrical activity of the electroence-phalogram (EEG). To achieve this suppression of the EEG activity (burst suppression, BS) high effector concentrations (Cet) of Propofol doses are needed. However, a protracted infusion of large amounts of Propofol to reach a BS during the operation can lead to accumulation and a protracted wake-up phase with poorer neurological assessability.
Somatosensory evoked potentials (SSEP), and trans-cranial Doppler (TCD) flow velocity in the middle cerebral artery are measured to detect ischemia. A significant decrease in TCD velocity and/or SSEPs amplitudes during cross-clamping of the internal carotid artery (ICA) gets treated with an adapted increase of arterial blood pressure or placement of a shunt. Intraoperative monitoring and recording of data in every patient undergoing CEA median nerve SEPs and MCA flow velocity have been constantly monitored by an additional intraoperative monitoring (IOM) technician who has been trained and certified in the assessment of intraoperative monitoring. The median nerve SEP amplitudes are recorded at least at these events: baseline value before skin incision, EEG burst suppression before cross clamping of the internal carotid artery, at time of ICA cross clamping, 10 minutes after cross clamping or immediately after placement of shunt (ICA clamping), reperfusion of ICA and haemostasis / end of surgery. The predefined criterion for temporary shunting was the reduction of more than 50% of the SEP amplitude.
Median nerve somatosensory evoked potentials (SEPs) were performed by stimulation at the wrist with a pair of needle electrodes (Inomed Germany®). This is a single pulse stimulation with 0.5 ms pulse duration and a low repetition rate ranging from 0.7 - 2.3 Hz. Recording is performed via corkscrew electrodes placed accordingly to the 10-20-EEG system on the patient scalp. For the right median nerve SEP C3´/Fz and for the left median nerve SEP C4´/Fz is chosen as standard derivation. Alternatively, Cz' or the contralateral Cp' served as reference to improve quality of recording. To improve the signal to noise ratio the responses are averaged 150-200 times.
The investigator use the somatosensive evoked potentials (SSEPs) to verify the functional integrity of the nervous system. Standardized surgical and anaesthesiological measures at the CEA with defined EEG endpoints and depending on the anaesthetic effect can - in normal EEG and SSEPs - effectively exclude severe global ischemia. The effects of burst suppression and the volatile anaesthetics on SSEPs were also investigated and showed no significant difference. Since 2016, motor-induced evoked potentials (MEPs) have also been used, which are, however, suppressed by volatile anaesthetics in a dose-dependent manner. On the other hand, Dexmedetomidine in combination with Propofol seems to suppress only insignificantly.
The indication spectrum for the centrally acting α2-agonist Dexmedetomidine has been increasingly extended since its approval in Switzerland. In addition to the use of Dexmedetomidine in the intensive care units, Dexmedetomidine is also increasingly being used perioperatively up to premedication in children. In some studies, an anaesthetic reduction of 40-60% could be achieved or the opioid consumption after the addition of a α2-agonist could be reduced by 50-75%. The blood pressure response to a Dexmedetomidine dose depends on the rate of infusion). In addition, administration of Dexmedetomidine does not result in respiratory depression or compromising of the respiratory tract. It has been shown that Dexmedetomidine can cause a "sleep-like" sedation state and this state can be interrupted by verbal stimuli), examined the EEG activity in sedations on voluntary subjects compared to a control group with physiological sleep pattern. In this study, it was shown that the EEG spindle activity in subjects with Dexmedetomidine infusion was comparable to that of a physiological non-rapid eye-movement (nonREM) sleep stage II in the control tests. The authors concluded from their investigations that a "sleep-like state" (stage II non-REM) can be achieved by the Dexmed-etomidine infusion. However, no data are currently known for practical use in carotid endarterectomy with Propofol and Dexmedetomidine in conjunction with electrophysiological studies (somatosensory evoked potentials (SSEP) and motor evoked potentials (MEP)).
In addition, there is a high risk of postoperative delirium (POD) in many of these patients. This was examined in a recently published Lancet study by Xian Su and colleagues in 700 patients with non-cardiac interventions in elderly patients). A reduction of the delirium incidence from 23% to 9% was found after a low-dose Dexmedetomidine dose of 0.1 μg/kg body weight/h. In addition, Dexmedetomidine is attributed a neuroprotective effect against ischemic and hypoxic influences). Other animals-experimental studies indicate neuroprotection in ischemic insult and subsequent reperfusion).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Randomised controlled prospective trial in two groups. Group 1 will receive anaesthesia with propofol and co-administration of dexmedetomidine in conjunction with electrophysiological studies measuring somatosensory evoked potentials (SSEPs) and motor evoked potentials (MEPs). Group 2 will receive standard anaesthesia with propofol alone, in conjunction with electro¬physio¬logical studies measuring SSEPs and MEPs.
| Arm | Type | Receives |
|---|---|---|
| Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies | Experimental | Drug: DexmedetomidineThe group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by continuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. |
| Group 2: Standard anaesthesia with propofol and electrophysiological studies | No intervention | –The group 2 receive standard anaesthesia management. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥18 years
- ASA physical status 1-4
- written informed consent provided.
Key exclusion criteria (11 listed)
- Age <18 years
- higher grade atrioventricular block without pacemaker
- severe hypovolaemia or bradycardia
- uncontrolled hyper- or hypotension
- hypersensibility concerning the active substance dexmedetomidine or any other component
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DexmedetomidineAlso: Dexdor(R), DexmedetomidineThe study participants are divided into two groups: Group 1 starts with a bolus of dexmedetomidine 0.4 µg/kg over 10 minutes, followed by con-tinuous infusion of dexmedetomidine 0.4 µg/kg/h until the end of burst suppression. Group 2 receives the standard anaesthesia management. | Drug | Group 1: Co-administration of dexmedetomidine and propofol with electrophysiological studies |
Primary outcome
Effect size concentration of propofol.
Time frame: until the operation
The primary study outcome is to determine whether the intervention reduces the effect size concentration of propofol.
1 secondary outcome
intraoperative propofol requirement
Time frame: until the operation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2020.
- Derived from this study: PubMed 39529482Vetter C, Meyer ER, Seidel K, Bervini D, Huber M, Krejci V. Co-administration of dexmedetomidine with total intravenous anaesthesia in carotid endarterectomy reduces requirements for propofol and improves haemodynamic stability: A single-centre, prospective, randomised controlled trial. Eur J Anaesthesiol. 2025 Mar 1;42(3):255-264. doi: 10.1097/EJA.0000000000002099. Epub 2024 Nov 11.
- Individual participant dataSharing planned: No
Related trials for Carotid Stenosis
Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Not yet recruitingObservational study
A Prospective, Multicenter, Single Arm Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT in Chinese Population
Carotid Artery Stenosis
Not yet recruitingObservational study
Vascular Health and Function in Cystic Fibrosis
Cystic Fibrosis, Endothelial Dysfunction
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christian cv Vetter, MD principal investigator
University of Bern
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Dexmedetomidine in people with Carotid Stenosis, run by Insel Gruppe AG, University Hospital Bern at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect size concentration of propofol. (time frame: until the operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04662177, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2020.